Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials-Reference-Cited by-同舟云学术

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials

Published:2012-10 Issue:1 Volume:78 Page:8-15
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Petrelli Fausto,Borgonovo Karen,Cabiddu Mary,Lonati Veronica,Barni Sandro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference52 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

4. Prognostic value of ERBB-1, VEGF, cyclin A FOS, JUN and MYC in patients with squamous cell lung carcinomas;Volm;Br J Cancer,1998

5. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival;Brabender;Clin Cancer Res,2001

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort;Journal of the American Academy of Dermatology;2024-07

2. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients;The Oncologist;2023-11-23

3. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors;Journal of Cutaneous Medicine and Surgery;2023-11

4. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings;Human Pathology;2023-10

5. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07